Subramanian and coauthors [72] reported that CSCs from head and neck squamous cell carcinoma decrease stemness markers as CD44, ALDH and vimentin but increase E-cadherin after treatments with two novel HSP90 activity inhibitors, Ku711 and Ku757. This evidence concerns the gene HSP90AB1 and head and neck squamous cell carcinoma.